Takeda Pharmaceutical Company Statistics

Total Valuation

Takeda Pharmaceutical Company has a market cap or net worth of GBP 33.22 billion. The enterprise value is 57.37 billion.

Market Cap	33.22B
Enterprise Value	57.37B

Important Dates

The next estimated earnings date is Thursday, January 30, 2025.

Earnings Date	Jan 30, 2025
Ex-Dividend Date	Sep 30, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.07%
Shares Change (QoQ)	+1.29%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.57B

Valuation Ratios

The trailing PE ratio is 21.99.

PE Ratio	21.99
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.16, with an EV/FCF ratio of 16.25.

EV / Earnings	37.99
EV / Sales	2.48
EV / EBITDA	8.16
EV / EBIT	17.17
EV / FCF	16.25

Financial Position

The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.81.

Current Ratio	1.28
Quick Ratio	0.66
Debt / Equity	0.81
Debt / EBITDA	4.07
Debt / FCF	8.28
Interest Coverage	5.49

Financial Efficiency

Return on equity (ROE) is 4.15% and return on invested capital (ROIC) is 3.29%.

Return on Equity (ROE)	4.15%
Return on Assets (ROA)	2.77%
Return on Capital (ROIC)	3.29%
Revenue Per Employee	480,416
Profits Per Employee	30,646
Employee Count	49,281
Asset Turnover	0.31
Inventory Turnover	1.31

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -6.76% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-6.76%
50-Day Moving Average	13.70
200-Day Moving Average	13.79
Relative Strength Index (RSI)	33.47
Average Volume (20 Days)	689

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Takeda Pharmaceutical Company had revenue of GBP 23.68 billion and earned 1.51 billion in profits. Earnings per share was 0.95.

Revenue	23.68B
Gross Profit	15.61B
Operating Income	3.40B
Pretax Income	1.40B
Net Income	1.51B
EBITDA	6.92B
EBIT	3.40B
Earnings Per Share (EPS)	0.95

Full Income Statement

Balance Sheet

The company has 4.47 billion in cash and 29.21 billion in debt, giving a net cash position of -24.74 billion.

Cash & Cash Equivalents	4.47B
Total Debt	29.21B
Net Cash	-24.74B
Net Cash Per Share	n/a
Equity (Book Value)	36.05B
Book Value Per Share	22.74
Working Capital	3.47B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.56 billion and capital expenditures -1.03 billion, giving a free cash flow of 3.53 billion.

Operating Cash Flow	4.56B
Capital Expenditures	-1.03B
Free Cash Flow	3.53B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 65.95%, with operating and profit margins of 14.38% and 6.38%.

Gross Margin	65.95%
Operating Margin	14.38%
Pretax Margin	5.93%
Profit Margin	6.38%
EBITDA Margin	29.22%
EBIT Margin	14.38%
FCF Margin	14.91%

Dividends & Yields

Takeda Pharmaceutical Company does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	-7.34%
Years of Dividend Growth	1
Payout Ratio	101.62%
Buyback Yield	-1.07%
Shareholder Yield	-1.07%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Takeda Pharmaceutical Company has an Altman Z-Score of 1.17. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.17
Piotroski F-Score	n/a